Topics

Leveraging the Growing Arsenal of ALK and ROS1 Inhibitors in NSCLC

09:42 EDT 29 Oct 2019 | OncLive

Nathan A. Pennell, MD, PhD, discusses the actionability of advanced ALK-positive and ROS1-positive non–small cell lung cancer and the drugs that have emerged in the frontline and second-line settings.

Original Article: Leveraging the Growing Arsenal of ALK and ROS1 Inhibitors in NSCLC

NEXT ARTICLE

More From BioPortfolio on "Leveraging the Growing Arsenal of ALK and ROS1 Inhibitors in NSCLC"

Quick Search

Relevant Topic

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...